New benzimidazole‐oxadiazole derivatives as potent VEGFR‐2 inhibitors: Synthesis, anticancer evaluation, and docking study
Drug Development Research · 2024
DOI: 10.1002/ddr.22218 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, 2024. Verfasst von Ulviye Acar Çevik und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, Eskişehir, Turkey. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor Receptor-2, Molecular Docking Simulation, Oxadiazoles, Antineoplastic Agents. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Anadolu Üniversitesi.
Abstract (Originalsprache)
We report herein, the design and synthesis of benzimidazole‐oxadiazole derivatives as new inhibitors for vascular endothelial growth factor receptor‐2 (VEGFR‐2). The designed members were assessed for their in vitro anticancer activity against three cancer cell lines and two normal cell lines; A549, MCF‐7, PANC‐1, hTERT‐HPNE and CCD‐19Lu. Compounds 4c and 4d were found to be the most effective compounds against three cancer cell lines. Compounds 4c and 4d were then tested for their in vitro VEGFR‐2 inhibitory activity, safety profiles, and selectivity indices using the normal hTERT‐HPNE and CCD‐19Lu cell lines. It was determined that compound 4c was the most effective and safe member of the produced chemical family. Vascular endothelial growth factor A (VEGFA) immunolocalizations of compounds 4c and 4d were evaluated relative to control by VEGFA immunofluorescence staining. Compounds 4c and 4d inhibited VEGFR‐2 enzyme with half‐maximal inhibitory concentration values of 0.475 ± 0.021 and 0.618 ± 0.028 µM, respectively. Molecular docking of the target compounds was carried out in the active site of VEGFR‐2 (Protein Data Bank: 4ASD).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, Eskişehir, Turkey.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Erciyes University, Kayseri, Turkey.
- Medicinal Plant, Drug and Scientific Research and Application Center (AUBIBAM), Eskişehir, Turkey.
- Department of Histology and Embryology, Sivas Cumhuriyet University, Sivas, Turkey.
- Department of Biochemistry, Faculty of Pharmacy, Cumhuriyet University, Sivas, Turkey.
ORCID-Profile: Ulviye Acar Çevik, Ismail Celik, Şennur Görgülü, Zafer Asım Kaplacıklı
Förderung
- Anadolu Üniversitesi
Zitieren
APA
Acar Çevik, U., Celik, I., Görgülü, Ş., Şahin Inan, Z. D., Bostancı, H. E., Özkay, Y., & Kaplacıklı, Z. A. (2024). New benzimidazole‐oxadiazole derivatives as potent VEGFR‐2 inhibitors: Synthesis, anticancer evaluation, and docking study. Drug Development Research. https://doi.org/10.1002/ddr.22218
Vancouver
Acar Çevik U, Celik I, Görgülü Ş, Şahin Inan ZD, Bostancı HE, Özkay Y, et al. New benzimidazole‐oxadiazole derivatives as potent VEGFR‐2 inhibitors: Synthesis, anticancer evaluation, and docking study. Drug Development Research. 2024. doi:10.1002/ddr.22218
BibTeX
@article{Acarevik2024,
author = {Acar Çevik, Ulviye and Celik, Ismail and Görgülü, Şennur and Şahin Inan, Zeynep Deniz and Bostancı, Hayrani Eren and Özkay, Yusuf and Kaplacıklı, Zafer Asım},
title = {New benzimidazole‐oxadiazole derivatives as potent VEGFR‐2 inhibitors: Synthesis, anticancer evaluation, and docking study},
journal = {Drug Development Research},
year = {2024},
doi = {10.1002/ddr.22218}
}
EUVIMED